SHANGHAI and GAITHERSBURG, Md. , Dec. 23, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB ), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced its participation in the following conferences in

- Global biotech index widely followed and tracked by investors and ETFs - IMAB added to the index upon first annual review since IPO - To be effective prior to the U.S. market open on Monday, December 21, 2020 SHANGHAI and GAITHERSBURG, Md. , Dec. 14, 2020 /PRNewswire/ -- I-Mab (the "Company")

SHANGHAI and GAITHERSBURG, Md., Dec. 4, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB ), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics, today announced the advancement of clinical

SHANGHAI and GAITHERSBURG, Md. , Dec. 1, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB ), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today filed a registration statement on Form F-1 with the Securities and

SHANGHAI and GAITHERSBURG, Md. , Dec. 1, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB ), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced the strengthening of its Scientific Advisory Board (" SAB

SHANGHAI and GAITHERSBURG, Md. , Nov. 13, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that it will hold a call with investors on Friday,

- Oral presentation highlights the unique epitope, pharmacological profile and anti-tumor properties of TJ210/MOR210 SHANGHAI and GAITHERSBURG, Md. , Nov. 11, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery,

- Initial monotherapy results demonstrate differentiated safety and PK profile and efficacy signal of lemzoparlimab for the treatment of relapsed/refractory malignancy   - I-Mab to host call for investors on November 9 at 8:30am ET SHANGHAI and GAITHERSBURG, Md. , Nov.

SHANGHAI, China , and GAITHERSBURG, MD ., Oct. 28, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced its participation in the following conferences

- Oral presentation will highlight the potent anti-tumor effects demonstrated by TJ210, a novel antibody that blocks C5aR by binding to a unique epitope SHANGHAI and GAITHERSBURG, Md. , Oct. 27, 2020 /PRNewswire/ --  I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company